Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.
Ontology highlight
ABSTRACT: Chimeric antigen receptor (CAR) T cells in solid tumors have so far yielded limited results, in terms of therapeutic effects, as compared to the dramatic results observed for hematological malignancies. Many factors involve both the tumor cells and the microenvironment. The lack of specific target antigens and severe, potentially fatal, toxicities caused by on-target off-tumor toxicities constitute major hurdles. Furthermore, the tumor microenvironment is usually characterized by chronic inflammation, the presence of immunosuppressive molecules, and immune cells that can reduce CAR T cell efficacy and facilitate antigen escape. Nonetheless, solid tumors are under investigation as possible targets despite their complexity, which represents a significant challenge. In preclinical mouse model
SUBMITTER: Boccalatte F
PROVIDER: S-EPMC9600451 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA